# Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke

> **NCT07519889** · — · NOT_YET_RECRUITING · sponsor: **CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.** · enrollment: 4500 (estimated)

## Conditions studied

- Acute Ischemic Stroke
- rhTNK-tPA

## Interventions

- **DRUG:** rhTNK-tPA
- **DRUG:** rt-PA

## Key facts

- **NCT ID:** NCT07519889
- **Lead sponsor:** CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2027-01-10
- **Final completion:** 2027-04-10
- **Target enrollment:** 4500 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07519889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07519889, "Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07519889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*